Duo Oncology Selected for Prestigious NCI SBIR Investor Initiatives Program

Pittsburgh (PRWEB) October 11, 2024 - Duo Oncology is proud to announce its selection for the National Cancer Institute’s Small Business Innovation Research (NCI SBIR) Investor Initiatives program (the “Program”). This Program selects SBIR awardees with promising cancer therapeutics technology and potential impact on patient care. Only 15 biopharmaceutical companies were selected from more than 100 applicants, highlighting the competitive nature of this Program. Through participation in the Program, Duo Oncology received expert feedback from industry reviewers, which has significantly helped the company de-risk its commercialization strategy and strengthen its value proposition.

CEO and co-founder Sam Rothstein, PhD, expressed his gratitude for this support, stating: “Being selected for the NCI SBIR Investor Initiatives program is a tremendous boost to our team. The expert feedback from the reviewers has been invaluable in improving our commercialization plans and will help us bring our innovative therapies to patients. This program helps accelerate our mission to transform cancer treatment and improve patient outcomes.”

Participation in the Program offers Duo Oncology valuable opportunities to connect with industry leaders and others. These connections are essential for the market-relevant development of Duo's therapies, particularly as they progress toward clinical trials and the treatment of cancer patients.